IND Gantt Chart Your lead candidate selection should flow seamlessly into the development phase. Simply provide a few details in the form below, and we’ll generate a Gantt chart with an estimated timeline for your IND or BLA milestones to help you plan accordingly. Every program is unique and should be evaluated on a case by case basis. Ask our advisory services to review your program and offer a customized solution and timeline in order to get your product to market as efficiently as possible. First Name * Last Name * Title Company * Email * Research Area -Select- Biosimilars Bone and Skeletal Disease Cardiovascular Cell and Gene Therapy Central Nervous System Dermatology Endocrinology Gastroenterology Infectious Disease Immunology Medical Device Metabolic Disease Musculoskeletal Oncology Ophthalmology Orphan Disease Reproductive Respiratory Vaccine Other Molecule Type * -Select- Biologic NCE My Test Article will be available by (or) I want my Audited Draft Report for Yes, I would like to receive email communications from Charles River and allow for my information to be used for any follow-up requests to identify potential products or services relevant to my needs. I agree. * required 1 Please note that this interactive tool is meant to provide an estimated timeline to help you better plan your IND program. Charles River is not committing to these dates at this time. Actual milestone dates would have to be confirmed by contacting us. Print W - Weeks Start date End date Start date End date 1 Timelines are based on an optimized IND program. They are subject to change and can be adapted on a case-by-case basis. 2 Includes 1-month long-term matrix stability. 3 Timeline based on the use of non-naive animals (if available in-house). If naive animals are required, add 6 weeks prior to dosing for delivery, acclimation and surgical procedures. 4 Can be incorporated as part of the definitive 28-day GLP studies, as needed. 1 Timelines are based on an optimized IND program. They are subject to change and can be adapted on a case-by-case basis. 2 If bridging ECL, development can be done for both species under the same method development study. 3 Safety pharmacology endpoints can be incorporated within definitive studies. 4 Suggested to use non-naive animals if available in-house. If naive animals are required, add 4-6 weeks for NHP acclimation and pretreatment time. firstname.lastname@example.org www.criver.com © 2019 Charles River Laboratories International, Inc.